-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, March 15 Recently, Fuan Pharmaceutical entered the administrative examination and approval stage with the imitation of escitalopram oxalate tablets reported for production in Category 4, and it is expected to be approved for production in the near future.
Escitalopram oxalate tablets are antidepressants.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2019 are close to 2 billion yuan.
Escitalopram oxalate tablets are antidepressants.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2019 are close to 2 billion yuan.
Escitalopram oxalate tablets are the single dextrorotatory optical isomer of the dicyclic hydrogen phthalate derivative racemic citalopram, which is used to treat depression and panic disorder.
Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability.
It is a first-line drug for the treatment of depression and has been included in the first batch of centralized procurement.
Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability.
It is a first-line drug for the treatment of depression and has been included in the first batch of centralized procurement.
Escitalopram oxalate tablets are the market leader in antidepressants.
According to data from Menet.
com, in 2019, the sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are close to 2 billion yuan, and its sales in 2020H1 Over 700 million yuan, down 21.
32% year-on-year.
According to data from Menet.
com, in 2019, the sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are close to 2 billion yuan, and its sales in 2020H1 Over 700 million yuan, down 21.
32% year-on-year.
At present, the competition pattern of escitalopram oxalate tablets in the domestic market is relatively good.
The manufacturers include the original researcher Lingbei and 6 imitation companies .
Among them, the product of Kelun Pharmaceutical, Dongting Pharmaceutical, Jingwei Pharmaceutical, West Point Pharmaceutical and Huahai Pharmaceutical has passed the consistency evaluation.
The manufacturers include the original researcher Lingbei and 6 imitation companies .
Among them, the product of Kelun Pharmaceutical, Dongting Pharmaceutical, Jingwei Pharmaceutical, West Point Pharmaceutical and Huahai Pharmaceutical has passed the consistency evaluation.
Review of Escitalopram Oxalate Tablets
Source: Mi Nei Net Consistency Evaluation Database
According to data from Meinenet, the listing application of escitalopram oxalate tablets from Dongyang Sun Pharmaceutical and Huayuan Pharmaceutical is under review and approval.
The registration status of this product of Fuan Pharmaceutical has been changed to "under review", if it is successfully approved, it will be deemed as over-evaluated.
The registration status of this product of Fuan Pharmaceutical has been changed to "under review", if it is successfully approved, it will be deemed as over-evaluated.
Source: Minet database
Medical News, March 15 Recently, Fuan Pharmaceutical entered the administrative examination and approval stage with the imitation of escitalopram oxalate tablets reported for production in Category 4, and it is expected to be approved for production in the near future.
Escitalopram oxalate tablets are antidepressants.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2019 are close to 2 billion yuan.
Escitalopram oxalate tablets are antidepressants.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2019 are close to 2 billion yuan.
Escitalopram oxalate tablets are the single dextrorotatory optical isomer of the dicyclic hydrogen phthalate derivative racemic citalopram, which is used to treat depression and panic disorder.
Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability.
It is a first-line drug for the treatment of depression and has been included in the first batch of centralized procurement.
Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability.
It is a first-line drug for the treatment of depression and has been included in the first batch of centralized procurement.
Escitalopram oxalate tablets are the market leader in antidepressants.
According to data from Menet.
com, in 2019, the sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are close to 2 billion yuan, and its sales in 2020H1 Over 700 million yuan, down 21.
32% year-on-year.
According to data from Menet.
com, in 2019, the sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are close to 2 billion yuan, and its sales in 2020H1 Over 700 million yuan, down 21.
32% year-on-year.
At present, the competition pattern of escitalopram oxalate tablets in the domestic market is relatively good.
The manufacturers include the original researcher Lingbei and 6 imitation companies .
Among them, the product of Kelun Pharmaceutical, Dongting Pharmaceutical, Jingwei Pharmaceutical, West Point Pharmaceutical and Huahai Pharmaceutical has passed the consistency evaluation.
The manufacturers include the original researcher Lingbei and 6 imitation companies .
Among them, the product of Kelun Pharmaceutical, Dongting Pharmaceutical, Jingwei Pharmaceutical, West Point Pharmaceutical and Huahai Pharmaceutical has passed the consistency evaluation.
Review of Escitalopram Oxalate Tablets
Source: Mi Nei Net Consistency Evaluation Database
According to data from Meinenet, the listing application of escitalopram oxalate tablets from Dongyang Sun Pharmaceutical and Huayuan Pharmaceutical is under review and approval.
The registration status of this product of Fuan Pharmaceutical has been changed to "under review", if it is successfully approved, it will be deemed as over-evaluated.
The registration status of this product of Fuan Pharmaceutical has been changed to "under review", if it is successfully approved, it will be deemed as over-evaluated.
Source: Minet database
Medical News, March 15 Recently, Fuan Pharmaceutical entered the administrative examination and approval stage with the imitation of escitalopram oxalate tablets reported for production in Category 4, and it is expected to be approved for production in the near future.
Escitalopram oxalate tablets are antidepressants.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2019 are close to 2 billion yuan.
Escitalopram oxalate tablets are antidepressants.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2019 are close to 2 billion yuan.
Escitalopram oxalate tablets are the single dextrorotatory optical isomer of the dicyclic hydrogen phthalate derivative racemic citalopram, which is used to treat depression and panic disorder.
Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability.
It is a first-line drug for the treatment of depression and has been included in the first batch of centralized procurement.
Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability.
It is a first-line drug for the treatment of depression and has been included in the first batch of centralized procurement.
Escitalopram oxalate tablets are the market leader in antidepressants.
According to data from Menet.
com, in 2019, the sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are close to 2 billion yuan, and its sales in 2020H1 Over 700 million yuan, down 21.
32% year-on-year.
Hospital hospital hospitalAccording to data from Menet.
com, in 2019, the sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are close to 2 billion yuan, and its sales in 2020H1 Over 700 million yuan, down 21.
32% year-on-year.
At present, the competition pattern of escitalopram oxalate tablets in the domestic market is relatively good.
The manufacturers include the original researcher Lingbei and 6 imitation companies .
Among them, the product of Kelun Pharmaceutical, Dongting Pharmaceutical, Jingwei Pharmaceutical, West Point Pharmaceutical and Huahai Pharmaceutical has passed the consistency evaluation.
Enterprise business enterpriseThe manufacturers include the original researcher Lingbei and 6 imitation companies .
Among them, the product of Kelun Pharmaceutical, Dongting Pharmaceutical, Jingwei Pharmaceutical, West Point Pharmaceutical and Huahai Pharmaceutical has passed the consistency evaluation.
Review of Escitalopram Oxalate Tablets
Source: Mi Nei Net Consistency Evaluation Database
According to data from Meinenet, the listing application of escitalopram oxalate tablets from Dongyang Sun Pharmaceutical and Huayuan Pharmaceutical is under review and approval.
The registration status of this product of Fuan Pharmaceutical has been changed to "under review", if it is successfully approved, it will be deemed as over-evaluated.
The registration status of this product of Fuan Pharmaceutical has been changed to "under review", if it is successfully approved, it will be deemed as over-evaluated.
Source: Minet database
